drugset
drugset / Trial / NCT02338518

Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients

NCT02338518 ↗

Phase 3 Unknown 297 enrolled Jinling Hospital, China
RandomizedParallel-groupOpen-labelTreatment

Summary

Chemotherapy is an important therapeutic method for patients with advanced gastric cancer. However, there is currently no established standard chemotherapeutic regimen in the preoperative or neoadjuvant treatment setting. The aim of our study was to compare the efficacy and toxicity between SEEOX and SOX regimens. The investigators estimate that combined intravenous and intra-arterial intensified SEEOX preoperative chemotherapy may be a safe and promising regimen for locally advanced or initially unresectable gastric cancer patients.

Timeline

Start
2015-01-04
Primary completion
2019-05-21
Completion
2023-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Epirubicin Small molecule 30 mg/m2 Other
Subject Etoposide Small molecule 80 mg/m2 Other
Subject Oxaliplatin Small molecule 100 mg/m2 Other
Subject Oxaliplatin Small molecule 130 mg/m2 Other
Subject S-1 Small molecule 80 mg/m2 Oral
Subject S-1 Small molecule 120 mg/m2 Oral

Indications

gastric cancer